ACR Concerns on the Scientific Integrity at the CDC On behalf of the American College of Rheumatology (ACR), we expres

Tweet Author

Tweet Content

ACR Concerns on the Scientific Integrity at the CDC On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to https://t.co/P2J7eZN07W

8 September 2025

APLAR 2025: What’s New in RA Management?

The unveiling of the updated 2025 recommendations for RA treatment, presented by Josef Smolen in the plenary session on the first day of the conference, sparked attention. Although not yet formally published, these updated recommendations represent a refined consensus that simplifies decision-making while reinforcing the importance of treat-to-target principles in RA.

QD Clinic: ILD, Emphysema, Both, or Neither?

8 September 2025

Addressing Disparities and Unequal Burdens in ILD

Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one unifying truth: they are almost always serious, progressive, and life-altering. But for many patients, the burden of disease does not fall evenly. We are increasingly learning that where you live, who you are, and the resources available to you, can strongly influence how ILD develops and worsens. Understanding these disparities is not about pointing fingers. Rather, it is about uncovering opportunities to deliver better, fairer care.

Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression did

Tweet Author

RheumNow

Tweet Content

Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective(OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://t.co/DbsJVZ16Zd

Future Treatment of ILD

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Admini

Tweet Author

RheumNow

Tweet Content

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/DPgDQsCWK9

Links

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease | RheumNow https://buff.ly/3X9lw9a?utm_content=bufferf457f&utm_medium=social&utm_source=tw…

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treat

Tweet Author

RheumNow

Tweet Content

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/sSzMvDUMf5

Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognos

Tweet Author

RheumNow

Tweet Content

Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/QLod6uj2Dj

Links

Comprehensive analysis of patients with rheumatoid arthritis associated interst… https://buff.ly/PUo9Aul

Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 5

Tweet Author

RheumNow

Tweet Content

Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/8IWXWZmWgE

Topics

ACR Concerns on the Scientific Integrity at the CDC On behalf of the American College of Rheumatology (ACR), we expres

QD Clinic: ILD, Emphysema, Both, or Neither?

Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression did

Future Treatment of ILD

In your rheumatic patients with ILD, who usually treats the ILD?

What determines which patients will be treated for ILD?

Which class of drugs do you most rely on in treating ILD:

Patients with ILD – what Immunosuppressants do you rely on?

With Autoimmune disease and ILD - what is the value of antifibrotics or IL-6 inhibitors?

What is the value of immunosuppressants (eg MMF) in ILD?

I treat autoimmune related ILD, because these patients have:

Which Guidelines for ILD in systemic autoimmune rheumatic disease (SARD) are you familiar with:

Which drug is proven to be “anti-fibrotic”?

Which is your practice setting?

Please select:

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Admini

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treat

Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognos

Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 5

Do you get our email newsletter?